Why the study?
Does memantine monotherapy improve cognitive and functional outcomes in patients with moderate-to-severe Alzheimer disease?
Population
350 patients with moderate-to-severe Alzheimer disease not receiving a cholinesterase inhibitor
Comparison
Memantine 20 mg/d monotherapy vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
24 weeks
Authors
Loading...
Memantine monotherapy does not improve cognitive outcomes versus placebo in moderate-to-severe Alzheimer disease; challenges efficacy assumptions and supports placebo-controlled reevaluation.
Does memantine monotherapy improve cognitive and functional outcomes in patients with moderate-to-severe Alzheimer disease?
Memantine monotherapy did not demonstrate a statistically significant benefit over placebo on primary cognitive outcomes at 24 weeks using prospectively defined analyses in patients with moderate-to-severe Alzheimer's disease.
Dyck et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: